Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:
• clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.
Locations
Other Locations
Mexico
Hospital General de Mexico Dr. Eduardo Liceaga
RECRUITING
Mexico City
Contact Information
Primary
Christian O Ramos Peñafiel, PhD
leukemiachop33@gmail.com
+52 55 27892000
Backup
Adán G Gallardo Rodriguez, PhD
nutriologo.agallardo8@gmail.com
+52 55 27892000
Time Frame
Start Date: 2023-11-20
Estimated Completion Date: 2024-10-30
Participants
Target number of participants: 83
Treatments
Control Group
Thalidomide 100mg-200mg PO daily alone or in combination with dexamethasone 40mg PO every 24 hours on days 1-4, 8-11 of each cycle.
Bortezomib Group
Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (VTD).
Related Therapeutic Areas
Sponsors
Leads: Hospital General de Mexico